JP2013541582A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013541582A5 JP2013541582A5 JP2013537287A JP2013537287A JP2013541582A5 JP 2013541582 A5 JP2013541582 A5 JP 2013541582A5 JP 2013537287 A JP2013537287 A JP 2013537287A JP 2013537287 A JP2013537287 A JP 2013537287A JP 2013541582 A5 JP2013541582 A5 JP 2013541582A5
- Authority
- JP
- Japan
- Prior art keywords
- adhd
- pharmaceutically acceptable
- lurasidone
- acid addition
- acceptable acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013537287A JP5855670B2 (ja) | 2010-11-08 | 2011-05-24 | 精神疾患の治療方法 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41108110P | 2010-11-08 | 2010-11-08 | |
| US61/411,081 | 2010-11-08 | ||
| JP2011033453 | 2011-02-18 | ||
| JP2011033453 | 2011-02-18 | ||
| PCT/JP2011/062314 WO2012063513A1 (en) | 2010-11-08 | 2011-05-24 | Method of treatment for mental disorders |
| JP2013537287A JP5855670B2 (ja) | 2010-11-08 | 2011-05-24 | 精神疾患の治療方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015240067A Division JP6470164B2 (ja) | 2010-11-08 | 2015-12-09 | 精神疾患の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013541582A JP2013541582A (ja) | 2013-11-14 |
| JP2013541582A5 true JP2013541582A5 (https=) | 2014-07-10 |
| JP5855670B2 JP5855670B2 (ja) | 2016-02-09 |
Family
ID=46020227
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013537287A Active JP5855670B2 (ja) | 2010-11-08 | 2011-05-24 | 精神疾患の治療方法 |
| JP2015240067A Active JP6470164B2 (ja) | 2010-11-08 | 2015-12-09 | 精神疾患の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015240067A Active JP6470164B2 (ja) | 2010-11-08 | 2015-12-09 | 精神疾患の治療方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (5) | US8258139B2 (https=) |
| EP (1) | EP2638038A4 (https=) |
| JP (2) | JP5855670B2 (https=) |
| CN (1) | CN103180315A (https=) |
| CA (1) | CA2814828C (https=) |
| WO (1) | WO2012063513A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103565776A (zh) * | 2012-07-25 | 2014-02-12 | 天津市汉康医药生物技术有限公司 | 一种稳定的鲁拉西酮胶囊药物组合物 |
| WO2014192868A1 (ja) * | 2013-05-30 | 2014-12-04 | 大日本住友製薬株式会社 | 環状アミノメチルピリミジン誘導体 |
| US10272080B2 (en) | 2013-09-13 | 2019-04-30 | Florida State University Research Foundation, Inc. | Selective dopamine D4 receptor agonists for treatment of working memory deficits |
| JP6594351B2 (ja) | 2014-06-16 | 2019-10-23 | ジョンソン、マッセイ、パブリック、リミテッド、カンパニー | 新規中間体を含むアルキル化アリールピペラジン及びアルキル化アリールピペリジン化合物の製造方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2800953B2 (ja) | 1990-07-06 | 1998-09-21 | 住友製薬株式会社 | 新規なイミド誘導体 |
| DK36291D0 (da) | 1991-03-01 | 1991-03-01 | Lundbeck & Co As H | Anvendelse af piperidylsubstituerede indolderivater til behandling af kognitive lidelser |
| GB9202915D0 (en) | 1992-02-12 | 1992-03-25 | Wellcome Found | Chemical compounds |
| IL110011A (en) | 1994-06-13 | 2004-09-27 | Yeda Res & Dev | Pharmacological preparations for the treatment of schizophrenia |
| WO1996014297A1 (en) | 1994-11-04 | 1996-05-17 | Sumitomo Pharmaceuticals Company, Limited | Novel lactam derivatives |
| JP3775823B2 (ja) | 1995-06-09 | 2006-05-17 | 大日本住友製薬株式会社 | 新規なイミド誘導体 |
| US5688798A (en) * | 1995-10-10 | 1997-11-18 | Hoffmann-La Roche Inc. | Pyrimidine compounds |
| EP1073432B1 (en) | 1998-04-14 | 2007-08-15 | The General Hospital Corporation | Use of d-serine or d-alanine for treating schizophrenia |
| JP2000281576A (ja) | 1999-03-29 | 2000-10-10 | Sumitomo Pharmaceut Co Ltd | イミド誘導体を含有するプロテオグリカン生成促進剤 |
| AR027134A1 (es) | 1999-12-30 | 2003-03-12 | Lundbeck & Co As H | Derivados de indol. |
| CA2422044A1 (en) | 2000-09-14 | 2002-03-21 | Gliatech, Inc. | Nitrogen-containing compounds and their use as glycine transport inhibitors |
| JP4868695B2 (ja) | 2000-09-22 | 2012-02-01 | 大日本住友製薬株式会社 | 崩壊性が良好な経口製剤 |
| CA2431041A1 (en) | 2001-01-02 | 2002-07-11 | Pharmacia & Upjohn Company | New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents |
| EP1395257A1 (en) | 2001-06-12 | 2004-03-10 | Elan Pharmaceuticals, Inc. | Macrocycles useful in the treatment of alzheimer's disease |
| JP4568463B2 (ja) | 2001-11-05 | 2010-10-27 | 独立行政法人科学技術振興機構 | ドレブリンａ発現抑制動物神経細胞及び非ヒトモデル動物 |
| JP4175800B2 (ja) | 2001-11-27 | 2008-11-05 | 住友化学株式会社 | イミド誘導体の製造方法 |
| EP1480629A1 (en) | 2002-02-08 | 2004-12-01 | Abbott Laboratories | Combination therapy for treatment of schizophrenia |
| EP1535616B1 (en) | 2002-08-22 | 2009-05-13 | Dainippon Sumitomo Pharma Co., Ltd. | Remedy for integration dysfunction syndrome |
| KR101113630B1 (ko) | 2003-06-23 | 2012-02-13 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 노인성 치매 치료제 |
| US20070160537A1 (en) | 2004-02-20 | 2007-07-12 | Takeo Ishiyama | In vivo screening method of therapeutic agent for memory/learning dysfunctions by schizophrenia |
| US7122683B2 (en) * | 2004-11-23 | 2006-10-17 | Pfizer Inc. | Amides useful as monoamine re-uptake inhibitors |
| US8283352B2 (en) * | 2005-06-13 | 2012-10-09 | Dainippon Sumitomo Pharma Co., Ltd. | Solubilization preparation |
| TW200812993A (en) | 2006-05-02 | 2008-03-16 | Lundbeck & Co As H | New uses of escitalopram |
| CN101663308A (zh) | 2006-10-30 | 2010-03-03 | 桑尔克斯药品公司 | N-甲基色胺钙五水合物(dcp)和基于它的治疗方法 |
| CA2682494C (en) * | 2007-04-04 | 2011-10-11 | Merck & Co., Inc. | Hexahydro-1h-4,7-methanoisoindole-1,3-dione compounds for treating psychiatric disorders |
| JP2008135074A (ja) | 2008-02-25 | 2008-06-12 | Fujitsu Ltd | 情報公開方法および情報公開装置 |
-
2011
- 2011-05-23 US US13/113,703 patent/US8258139B2/en active Active
- 2011-05-24 CN CN2011800528248A patent/CN103180315A/zh active Pending
- 2011-05-24 WO PCT/JP2011/062314 patent/WO2012063513A1/en not_active Ceased
- 2011-05-24 JP JP2013537287A patent/JP5855670B2/ja active Active
- 2011-05-24 CA CA2814828A patent/CA2814828C/en active Active
- 2011-05-24 EP EP11840252.8A patent/EP2638038A4/en not_active Withdrawn
-
2012
- 2012-07-20 US US13/555,044 patent/US9259423B2/en active Active
-
2015
- 2015-12-09 JP JP2015240067A patent/JP6470164B2/ja active Active
-
2016
- 2016-01-13 US US14/995,044 patent/US10098875B2/en active Active
- 2016-01-13 US US14/994,939 patent/US9827242B2/en active Active
-
2018
- 2018-09-24 US US16/139,647 patent/US20190022091A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014014262A2 (pt) | nanopartículas; composição farmacêutica; método de administrar um ou mais agentes terapêuticos, profiláticos, e/ou diagnósticos a um paciente em necessidade dos mesmos e método de preparação das partículas. | |
| CY1120049T1 (el) | (2s)-ν-[(1s)-1-κυανο-2-φαινυλαιθυλ]-1,4-οξαζεπαν-2-καρβοξαμιδια ως αναστολεις της διπεπτιδυλικης πεπτιδασης i | |
| JP2012255026A5 (https=) | ||
| JP2010529118A5 (https=) | ||
| JP2014528474A5 (https=) | ||
| JP2013525444A5 (https=) | ||
| JP2013509429A5 (https=) | ||
| CY1119575T1 (el) | Ενωσεις υποκατεστημενης βενζαλδεϋδης και μεθοδοι για τη χρηση τους στην αυξηση της οξυγονωσης του ιστου | |
| JP2014521735A5 (https=) | ||
| UA115139C2 (uk) | Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту | |
| JP2015524444A5 (https=) | ||
| JP2016517888A5 (https=) | ||
| BR112012003283A2 (pt) | sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, composição farmacêutica, produto, kit, uso de um sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, e, método de introdução de uma molécula de medicamento no citosol de uma célula em um paciente. | |
| JP2013541583A5 (https=) | ||
| JP2013519675A5 (https=) | ||
| JP2015530389A5 (https=) | ||
| MX343620B (es) | Forma polimorfica de clorhidrato de pridopidina. | |
| JP2019535760A5 (ja) | ガボキサドールを用いた注意欠陥多動性障害（ａｄｈｄ）の治療方法 | |
| PH12014502447A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| JP2016516074A5 (https=) | ||
| MD4369B1 (ro) | Utilizarea glicopirolatului pentru tratarea tahicardiei, doză unică, dispozitiv de administrare, metodă de tratament şi profilaxie a tahicardiei | |
| CY1119597T1 (el) | Συνθεσεις και μεθοδοι για υπερκεραση αντοχης σε τραμαδολη | |
| JP2014512355A5 (https=) | ||
| JP2013541582A5 (https=) | ||
| CO7170176A2 (es) | Nuevo compuesto que tiene la capacidad para inhibir la enzima deshidrogenasa11b-hidroxiesteroide tipo 1(11b-hsd1) o sal farmaceúticamente aceptable del mismo, método para producir el mismo, y composición farmaceútica que contiene el mismo como ingrediente activo |